



Date of publication: 6th February 2009

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 3 - 2009

Revised Factor VIII specification for Methylene Blue-treated cryoprecipitate

Applies to the Guidelines for the Blood Transfusion Services in the United Kingdom – 7th Edition 2005

The factor VIII specification for Methylene Blue-treated plasma is lower than for standard FFP, whereas currently the same specification is used for Methylene Blue-treated cryoprecipitate and standard cryoprecipitate. Perhaps unsurprisingly this standard has proved challenging to meet, without increasing the cryoprecipitate volume to larger than desirable levels. This change notice provides a reduced Factor VIII content specification for Methylene Blue-treated cryoprecipitate. The fibrinogen specification, fibrinogen replacement being the major reason cryoprecipitate is prescribed, remains unchanged. (*Background paper JPAC 08-74*)

Please delete:

8.25 Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted

Table 8.20 Cryoprecipitate, methylene blue treated and removed, leucocyte depleted – additional tests

Parameter	Frequency of test	Specification
FVIII:C		>70 IU/unit

Replace with:

8.25 Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted

Table 8.20 Cryoprecipitate, methylene blue treated and removed, leucocyte depleted – additional tests

Parameter	Frequency of test	Specification
FVIII:C		>50 IU/unit

Dr Sheila MacLennan
Professional Director - Joint UKBTS/NIBSC Professional Advisory Committee

☎ Direct Dial: (0113) 214 8638

✉ sheila.maclennan@nhsbt.nhs.uk